Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise (CARDIBOX) (CARDIBOX)
Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise
研究概览
详细说明
The investigators aim to improve knowledge of the association between epicardial adipose tissue, myocardial lipid content, and left ventricular regional myocardial function.
In this protocol, obese adolescents are recruited undergoing a 3-month lifestyle intervention residential program. Adolescents from the intervention group will be enrolled at the obesity center for the whole school year. The obesity center employs a multidisciplinary team to provide the best weight management care to adolescents during their stay. The weight loss program is an integral part of the obesity center program and fundamentally combines physical activity with a normocaloric diet monitored by a dietician. The physical activity program consists of two training sessions (aerobic and resistance training) per week. Moreover, adolescents will be engaged in two additional sessions per week, consisting in recreational activities such as ball and racquet games, trekking, snowshoeing or swimming.
There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.
Statistical analysis will be performed using Stata software (version 13; Stata-Corp, College Station, Tex., USA). All statistical tests will be two-sided and p inferior to 0.05 will be considered significant. Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of numbers, mean standard deviation or median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results. The main analysis will be performed with the Stata software (version 13, StataCorp, College Station). All statistical tests will be carried out at a risk of error of first species α set at 5%. Most of the analysis of the secondary evaluation criteria will be exploratory in nature and may lack power in terms of numbers. As discussed by Feise in 2002,104 the adjustment of the risk of error of 1st species will not be systematically proposed, but case by case in view of clinical considerations and not only statistical (e.g. Sidak correction for the analysis of correlation coefficients).
Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of standard deviation or mean median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results.
Intergroup comparisons will be systematically conducted without adjustment and by adjusting for factors whose distribution could be unbalanced between groups. Patients will be described and compared between groups at inclusion according to the following variables: compliance with eligibility criteria, epidemiological characteristics, clinical characteristics and characteristics of possible treatments. The baseline comparability of the two groups will be assessed on the main characteristics of the participants and potential factors associated with the primary outcome. A possible difference between the two groups on one of these characteristics will be determined according to clinical considerations and not solely statistical ones.
研究类型
注册 (预期的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Clermont-Ferrand、法国、63000
- CHU de Clermont-Ferrand
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- age between 12 and 16 years old
- mature (menarche)
- suitable for physical activity
- able to give an informative consent
- affiliated at French insurance company
- consent from the legal representatives
- For obese adolescents: BMI greater than the 97th percentile of national curves.
- For the control group: to be normal-weighted (no obesity if overweight, <85th percentile of national curves).
Exclusion Criteria:
- Medical or surgical history judged by the investigator as incompatible with the study
- Drugs that may interfere with the study results
- Cardiovascular, hepatic, psychiatric, renal, or endocrinological diseases
- Smoking
- Alcohol consumption
- Intense physical activity in competition
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Obese adolescents
BMI greater than the 97th percentile of national curves.
Participants will follow a 3-month lifestyle intervention
|
Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week. There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only. |
|
无干预:Control group
to be normal-weighted (no obesity if overweight, <85th percentile of national curves).
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
cardiac ectopic fat deposits
大体时间:Month 3
|
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
|
Month 3
|
|
cardiac ectopic fat deposits
大体时间:Day 0
|
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
|
Day 0
|
|
cardiac ectopic fat deposits
大体时间:Day 0
|
Quantification of cardiac ectopic fat deposits (volume using MRI)
|
Day 0
|
|
cardiac ectopic fat deposits
大体时间:Month 3
|
Quantification of cardiac ectopic fat deposits (volume using MRI)
|
Month 3
|
|
cardiac ectopic fat deposits
大体时间:Month 3
|
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
|
Month 3
|
|
cardiac ectopic fat deposits
大体时间:Day 0
|
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
|
Day 0
|
|
left myocardial regional function
大体时间:Month 3
|
left myocardial regional function (echocardiography)
|
Month 3
|
|
left myocardial regional function
大体时间:Month 3
|
left myocardial regional function (MRI)
|
Month 3
|
|
left myocardial regional function
大体时间:Day 0
|
left myocardial regional function (echocardiography)
|
Day 0
|
|
left myocardial regional function
大体时间:Day 0
|
left myocardial regional function (MRI)
|
Day 0
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
macrovascularisation
大体时间:Day 0
|
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
|
Day 0
|
|
macrovascularisation
大体时间:Month 3
|
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
|
Month 3
|
|
microvascularisation
大体时间:Month 3
|
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
|
Month 3
|
|
microvascularisation
大体时间:Day 0
|
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
|
Day 0
|
|
microvascularisation
大体时间:Day 0
|
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
|
Day 0
|
|
microvascularisation
大体时间:Month 3
|
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
|
Month 3
|
|
microvascularisation
大体时间:Month 3
|
measure of microvascular perfusion using Iontophoresis procedure
|
Month 3
|
|
microvascularisation
大体时间:Day 0
|
measure of microvascular perfusion using Iontophoresis procedure
|
Day 0
|
|
microvascularisation
大体时间:Day 0
|
measure of microvascular perfusion using flowmotion
|
Day 0
|
|
microvascularisation
大体时间:Month 3
|
measure of microvascular perfusion using flowmotion
|
Month 3
|
|
heart rate variability
大体时间:Month 3
|
measure of heart rate variability using a holter
|
Month 3
|
|
heart rate variability
大体时间:Day 0
|
measure of heart rate variability using a holter
|
Day 0
|
|
skin conductance
大体时间:Day 0
|
measure of skin conductance using Wristband electrodes - Empatica E4
|
Day 0
|
|
skin conductance
大体时间:Month 3
|
measure of skin conductance using Wristband electrodes - Empatica E4
|
Month 3
|
|
Liver steatosis
大体时间:Month 3
|
measure of liver steatosis by MRI
|
Month 3
|
|
Liver steatosis
大体时间:Day 0
|
measure of liver steatosis by MRI
|
Day 0
|
|
Liver steatosis
大体时间:Day 0
|
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
|
Day 0
|
|
Liver steatosis
大体时间:Month 3
|
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
|
Month 3
|
|
Liver steatosis
大体时间:month 3
|
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
|
month 3
|
|
Liver steatosis
大体时间:Day 0
|
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
|
Day 0
|
|
Liver fibrosis
大体时间:Day 0
|
measure of liver fibrosis by fibroscanner (liver stiffness)
|
Day 0
|
|
Liver fibrosis
大体时间:Month 3
|
measure of liver fibrosis by fibroscanner (liver stiffness)
|
Month 3
|
|
Liver fibrosis
大体时间:Month 3
|
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
|
Month 3
|
|
Liver fibrosis
大体时间:Day 0
|
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
|
Day 0
|
|
blood pressure
大体时间:Day0
|
measure of blood pressure using sphygmomanometer
|
Day0
|
|
blood pressure
大体时间:month 3
|
measure of blood pressure using sphygmomanometer
|
month 3
|
|
Fitness
大体时间:Month 3
|
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
|
Month 3
|
|
Fitness
大体时间:Day 0
|
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
|
Day 0
|
|
muscle mass
大体时间:Month 3
|
measure of muscle mass using impedancemeter
|
Month 3
|
|
fat mass
大体时间:Month 3
|
measure of muscle mass using impedancemeter
|
Month 3
|
|
bone structure
大体时间:Month 3
|
measure of muscle mass using impedancemeter
|
Month 3
|
|
muscle mass
大体时间:Day 0
|
measure of muscle mass using impedancemeter
|
Day 0
|
|
fat mass
大体时间:Day 0
|
measure of muscle mass using impedancemeter
|
Day 0
|
|
bone structure
大体时间:Day 0
|
measure of muscle mass using impedancemeter
|
Day 0
|
|
muscle mass
大体时间:Day 0
|
measure of muscle mass using Densitometry X-ray absorption
|
Day 0
|
|
fat mass
大体时间:Day 0
|
measure of muscle mass using Densitometry X-ray absorption
|
Day 0
|
|
bone structure
大体时间:Day 0
|
measure of muscle mass using Densitometry X-ray absorption
|
Day 0
|
|
muscle mass
大体时间:Month 3
|
measure of muscle mass using Densitometry X-ray absorption
|
Month 3
|
|
fat mass
大体时间:Month 3
|
measure of muscle mass using Densitometry X-ray absorption
|
Month 3
|
|
bone structure
大体时间:Month 3
|
measure of muscle mass using Densitometry X-ray absorption
|
Month 3
|
|
muscle mass
大体时间:Month 3
|
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
|
Month 3
|
|
fat mass
大体时间:Month 3
|
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
|
Month 3
|
|
bone structure
大体时间:Month 3
|
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
|
Month 3
|
|
muscle mass
大体时间:Day 0
|
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
|
Day 0
|
|
fat mass
大体时间:Day 0
|
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
|
Day 0
|
|
bone structure
大体时间:Day 0
|
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
|
Day 0
|
|
muscle mass
大体时间:Day 0
|
measure of muscle mass using Quantitative ultrasounds (QUS)
|
Day 0
|
|
fat mass
大体时间:Day 0
|
measure of muscle mass using Quantitative ultrasounds (QUS)
|
Day 0
|
|
bone structure
大体时间:Day 0
|
measure of muscle mass using Quantitative ultrasounds (QUS)
|
Day 0
|
|
muscle mass
大体时间:Month 3
|
measure of muscle mass using Quantitative ultrasounds (QUS)
|
Month 3
|
|
fat mass
大体时间:Month 3
|
measure of muscle mass using Quantitative ultrasounds (QUS)
|
Month 3
|
|
bone structure
大体时间:Month 3
|
measure of muscle mass using Quantitative ultrasounds (QUS)
|
Month 3
|
|
depression
大体时间:Day 0
|
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
|
Day 0
|
|
depression
大体时间:Month 3
|
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
|
Month 3
|
|
anxiety
大体时间:Day 0
|
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
|
Day 0
|
|
anxiety
大体时间:Month 3
|
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
|
Month 3
|
|
General health
大体时间:Day 0
|
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
|
Day 0
|
|
General health
大体时间:Month 3
|
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
|
Month 3
|
|
Stress
大体时间:day 0
|
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
|
day 0
|
|
Stress
大体时间:Month 3
|
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
|
Month 3
|
|
Fatigue
大体时间:Day 0
|
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
|
Day 0
|
|
Fatigue
大体时间:Month 3
|
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
|
Month 3
|
|
Sleep
大体时间:day 0
|
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
|
day 0
|
|
Sleep
大体时间:Month 3
|
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
|
Month 3
|
|
Burnout
大体时间:day 0
|
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
|
day 0
|
|
Burnout
大体时间:Month 3
|
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
|
Month 3
|
|
Mindfulness
大体时间:Day 0
|
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
|
Day 0
|
|
Mindfulness
大体时间:Month 3
|
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
|
Month 3
|
|
Coping
大体时间:Day 0
|
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
|
Day 0
|
|
Coping
大体时间:Month 3
|
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
|
Month 3
|
|
Emotions
大体时间:Day 0
|
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
|
Day 0
|
|
Emotions
大体时间:Month 3
|
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
|
Month 3
|
|
Perception of work
大体时间:Day 0
|
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree).
It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
|
Day 0
|
|
Perception of work
大体时间:Month 3
|
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree).
It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
|
Month 3
|
|
Self-efficacy
大体时间:Day 0
|
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
|
Day 0
|
|
Self-efficacy
大体时间:Month 3
|
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
|
Month 3
|
|
Alexithymia
大体时间:Day 0
|
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
|
Day 0
|
|
Alexithymia
大体时间:Month 3
|
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
|
Month 3
|
|
Illness perception
大体时间:Day 0
|
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
|
Day 0
|
|
Illness perception
大体时间:Month 3
|
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
|
Month 3
|
|
Metacognition
大体时间:Day 0
|
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
|
Day 0
|
|
Metacognition
大体时间:Month 3
|
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
|
Month 3
|
|
Time perception
大体时间:Day 0
|
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale.
It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
|
Day 0
|
|
Time perception
大体时间:Month 3
|
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale.
It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
|
Month 3
|
|
Physical activity
大体时间:Day 0
|
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
|
Day 0
|
|
Physical activity
大体时间:Month 3
|
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
|
Month 3
|
|
Life style
大体时间:Day 0
|
life style is assessed with a questionnaire on coffee consumption, food intake, etc
|
Day 0
|
|
Life style
大体时间:Month 3
|
life style is assessed with a questionnaire on coffee consumption, food intake, etc
|
Month 3
|
|
cholesterol
大体时间:Day 0
|
measure by blood analyses to evaluate alloplastic load
|
Day 0
|
|
triglycerides
大体时间:Day 0
|
measure by blood analyses to evaluate alloplastic load
|
Day 0
|
|
cholesterol
大体时间:Month 3
|
measure by blood analyses to evaluate alloplastic load
|
Month 3
|
|
triglycerides
大体时间:Month 3
|
measure by blood analyses to evaluate alloplastic load
|
Month 3
|
|
Cortisol
大体时间:Day 0
|
hormone measure by blood analyses to evaluate alloplastic load
|
Day 0
|
|
Cortisol
大体时间:Month 3
|
hormone measure by blood analyses to evaluate alloplastic load
|
Month 3
|
|
DHEAS
大体时间:day 0
|
hormone measure by blood analyses to evaluate alloplastic load
|
day 0
|
|
DHEAS
大体时间:Month 3
|
hormone measure by blood analyses to evaluate alloplastic load
|
Month 3
|
|
BDNF
大体时间:Day 0
|
proteins measure by blood analyses to evaluate alloplastic load
|
Day 0
|
|
BDNF
大体时间:Month 3
|
proteins measure by blood analyses to evaluate alloplastic load
|
Month 3
|
|
CRP
大体时间:Day 0
|
proteins measure by blood analyses to evaluate alloplastic load
|
Day 0
|
|
pro-inflammatory cytokines
大体时间:Day 0
|
proteins measure by blood analyses to evaluate alloplastic load
|
Day 0
|
|
TNF alpha
大体时间:Day 0
|
proteins measure by blood analyses to evaluate alloplastic load
|
Day 0
|
|
CRP
大体时间:Month 3
|
proteins measure by blood analyses to evaluate alloplastic load
|
Month 3
|
|
pro-inflammatory cytokines
大体时间:Month 3
|
proteins measure by blood analyses to evaluate alloplastic load
|
Month 3
|
|
TNF alpha
大体时间:Month 3
|
proteins measure by blood analyses to evaluate alloplastic load
|
Month 3
|
|
NPY
大体时间:Month 3
|
proteins measure by blood analyses to evaluate alloplastic load
|
Month 3
|
|
NPY
大体时间:Day 0
|
proteins measure by blood analyses to evaluate alloplastic load
|
Day 0
|
|
Leptin
大体时间:Day 0
|
measure by blood analyses to evaluate appetite regulation
|
Day 0
|
|
Leptin
大体时间:Month 3
|
measure by blood analyses to evaluate appetite regulation
|
Month 3
|
|
Ghrelin
大体时间:Day 0
|
measure by blood analyses to evaluate appetite regulation
|
Day 0
|
|
Ghrelin
大体时间:Month 3
|
measure by blood analyses to evaluate appetite regulation
|
Month 3
|
|
NPY
大体时间:day 0
|
measure by blood analyses to evaluate appetite regulation
|
day 0
|
|
NPY
大体时间:Month 3
|
measure by blood analyses to evaluate appetite regulation
|
Month 3
|
|
adiponectine
大体时间:Day 0
|
measure by blood analyses to evaluate appetite regulation
|
Day 0
|
|
adiponectine
大体时间:Month 3
|
measure by blood analyses to evaluate appetite regulation
|
Month 3
|
|
CCK
大体时间:Day 0
|
measure by blood analyses to evaluate appetite regulation
|
Day 0
|
|
Month 3
大体时间:Day 0
|
measure by blood analyses to evaluate appetite regulation
|
Day 0
|
|
Insulin
大体时间:Day 0
|
measure by blood analyses to evaluate glucid metabolism
|
Day 0
|
|
Insulin
大体时间:Month 3
|
measure by blood analyses to evaluate glucid metabolism
|
Month 3
|
|
HbA1c
大体时间:Day 0
|
measure by blood analyses to evaluate glucid metabolism
|
Day 0
|
|
HbA1c
大体时间:Month 3
|
measure by blood analyses to evaluate glucid metabolism
|
Month 3
|
|
glucose
大体时间:Day 0
|
measure by blood analyses to evaluate glucid metabolism
|
Day 0
|
|
glucose
大体时间:Month 3
|
measure by blood analyses to evaluate glucid metabolism
|
Month 3
|
|
Albumin
大体时间:Day 0
|
measure by blood analyses to evaluate protid metabolism
|
Day 0
|
|
Albumin
大体时间:Month 3
|
measure by blood analyses to evaluate protid metabolism
|
Month 3
|
|
transthyretin
大体时间:Day 0
|
measure by blood analyses to evaluate protid metabolism
|
Day 0
|
|
transthyretin
大体时间:Month 3
|
measure by blood analyses to evaluate protid metabolism
|
Month 3
|
|
Homeostasis
大体时间:Day 0
|
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
|
Day 0
|
|
Homeostasis
大体时间:Month 3
|
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
|
Month 3
|
|
Osteoresorption
大体时间:Day 0
|
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
|
Day 0
|
|
Osteoresorption
大体时间:Month 3
|
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
|
Month 3
|
|
Osteoformation
大体时间:Day 0
|
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
|
Day 0
|
|
Osteoformation
大体时间:Month 3
|
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
|
Month 3
|
|
VEGF
大体时间:Day 0
|
measure by blood analyses to evaluate cardiovascular function
|
Day 0
|
|
VEGF
大体时间:Month 3
|
measure by blood analyses to evaluate cardiovascular function
|
Month 3
|
|
PAI1
大体时间:Day 0
|
measure by blood analyses to evaluate cardiovascular function
|
Day 0
|
|
PAI1
大体时间:Month 3
|
measure by blood analyses to evaluate cardiovascular function
|
Month 3
|
|
weight
大体时间:Day 0
|
measure of weight in kilograms
|
Day 0
|
|
weight
大体时间:Month 3
|
measure of weight in kilograms
|
Month 3
|
|
waist circumference
大体时间:Day 0
|
measure of waist circumference in centimetres
|
Day 0
|
|
waist circumference
大体时间:Month 3
|
measure of waist circumference in centimetres
|
Month 3
|
合作者和调查者
合作者
研究记录日期
研究主要日期
学习开始 (预期的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- RBHP 2019 DUTHEIL
- 2019-A01804-53 (其他标识符:ANSM)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.